Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 for participating patients. They also more deeply discount the drugs for employers and health plans that contract with ...

Evernorth said in an announcement that through its Express Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The company's Evernorth Health Services subsidiary has launched a pharmacy benefit offering that caps monthly copayments for Wegovy and Zepbound, two blockbuster glucagon-like peptide-1 agonists ...

Zepbound (tirzepatide) is a prescription drug that’s used for weight loss and obstructive sleep apnea in certain adults. Zepbound comes as a liquid solution inside prefilled injection pens. You ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

The benefit could nudge more Evernorth clients to cover GLP-1s. Currently, only half of its employer clients cover drugs like Wegovy and Zepbound for weight management, executives said on a call ...

For Lilly's Zepbound, the list price is roughly $1,100 per month, while the net price is $725. These new arrangements by Evernorth and CVS Caremark could bring those net prices even lower for ...